Entero Therapeutics Q1 2026 Earnings Report

Entero Therapeutics EPS Results

• Actual EPS: -$0.82
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Entero Therapeutics Revenue Results

• Actual Revenue: $0.04 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Entero Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/27/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Entero Therapeutics (NASDAQ:GRDX) is a clinical-stage biopharmaceutical company focused on developing orally delivered therapies for gastrointestinal diseases. The company’s research programs target conditions in which localized treatment within the digestive tract may offer benefits over therapies that act throughout the body.

Entero’s development pipeline has included niclosamide-based therapies being investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. The company has also developed adrulipase, an orally administered recombinant enzyme intended as a potential treatment for exocrine pancreatic insufficiency associated with conditions including chronic pancreatitis and cystic fibrosis.

The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics as it concentrated its strategy on gastrointestinal therapeutics. Entero is headquartered in the United States and advances its programs through clinical development and collaborations. No information about approved commercial products or a broader operating footprint is included here because the company’s publicly available materials primarily describe it as a development-stage biotechnology business.